BRPI0906846A2 - Beta-lactamas terapêuticas. - Google Patents

Beta-lactamas terapêuticas.

Info

Publication number
BRPI0906846A2
BRPI0906846A2 BRPI0906846-5A BRPI0906846A BRPI0906846A2 BR PI0906846 A2 BRPI0906846 A2 BR PI0906846A2 BR PI0906846 A BRPI0906846 A BR PI0906846A BR PI0906846 A2 BRPI0906846 A2 BR PI0906846A2
Authority
BR
Brazil
Prior art keywords
lactams
therapeutic beta
beta
therapeutic
Prior art date
Application number
BRPI0906846-5A
Other languages
English (en)
Portuguese (pt)
Inventor
Danny T Dinh
David W Old
Robert M Burk
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of BRPI0906846A2 publication Critical patent/BRPI0906846A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0906846-5A 2008-01-18 2009-01-14 Beta-lactamas terapêuticas. BRPI0906846A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2217208P 2008-01-18 2008-01-18
US12/352,903 US8063033B2 (en) 2008-01-18 2009-01-13 Therapeutic beta-lactams
PCT/US2009/030894 WO2009091764A2 (en) 2008-01-18 2009-01-14 Therapeutic beta-lactams

Publications (1)

Publication Number Publication Date
BRPI0906846A2 true BRPI0906846A2 (pt) 2015-07-07

Family

ID=40876971

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0906846-5A BRPI0906846A2 (pt) 2008-01-18 2009-01-14 Beta-lactamas terapêuticas.

Country Status (7)

Country Link
US (1) US8063033B2 (enExample)
EP (1) EP2321304A2 (enExample)
JP (1) JP2011510009A (enExample)
AU (1) AU2009205477A1 (enExample)
BR (1) BRPI0906846A2 (enExample)
CA (1) CA2712264A1 (enExample)
WO (1) WO2009091764A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8420628B2 (en) * 2005-05-06 2013-04-16 Allergan, Inc. Substituted beta-lactams
US7772392B2 (en) * 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
WO2008144623A1 (en) * 2007-05-23 2008-11-27 Allergan, Inc. Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure
US8440819B2 (en) * 2008-02-22 2013-05-14 Allergan, Inc. Therapeutic substituted beta-lactams
US8202855B2 (en) * 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
ES2145122T3 (es) 1992-12-16 2000-07-01 Agouron Pharma Compuestos antiproliferantes de 5-tiapirimidinona y 5-selenopirimidinona sustituidos.
US5462968A (en) 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5698598A (en) 1995-08-04 1997-12-16 Allergan EP2 -receptor agonists as agents for lowering intraocular pressure
US6090847A (en) 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
EP1339678B1 (en) 2000-11-27 2007-09-26 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
KR20040015364A (ko) 2001-07-16 2004-02-18 에프. 호프만-라 로슈 아게 Ｅｐ4 수용체 작용물질로서의 프로스타글란딘 유사체
CN1617868A (zh) 2001-11-05 2005-05-18 阿勒根公司 作为EP2－受体激动剂的ω－环烷基17－杂芳基前列腺素E2 类似物
EP1487437B1 (en) 2002-03-18 2006-08-16 Pfizer Products Inc. Use of selective ep4 receptor agonists for the treatment of diseases
US7091231B2 (en) 2004-12-10 2006-08-15 Allergan, Inc. 12-Aryl prostaglandin analogs
WO2006121822A1 (en) 2005-05-06 2006-11-16 Allergan, Inc. USE OF β-LACTAMS FOR THE TREATMENTOF IBD AND GLAUCOMA
US8420628B2 (en) * 2005-05-06 2013-04-16 Allergan, Inc. Substituted beta-lactams
US7674786B2 (en) * 2005-05-06 2010-03-09 Allergan, Inc. Therapeutic β-lactams
US7772392B2 (en) * 2005-05-06 2010-08-10 Allergan, Inc. Therapeutic substituted β-lactams
US7427685B2 (en) * 2005-12-06 2008-09-23 Allergan, Inc. Therapeutic substituted cyclopentanes
US20070254920A1 (en) * 2006-04-26 2007-11-01 Aerie Pharmaceuticals, Inc. Prodrug derivatives of acids using alcohols with homotopic hydroxy groups and methods for their preparation and use
US8202855B2 (en) * 2008-03-04 2012-06-19 Allergan, Inc Substituted beta-lactams

Also Published As

Publication number Publication date
CA2712264A1 (en) 2009-07-23
EP2321304A2 (en) 2011-05-18
US20090186866A1 (en) 2009-07-23
US8063033B2 (en) 2011-11-22
WO2009091764A2 (en) 2009-07-23
AU2009205477A1 (en) 2009-07-23
JP2011510009A (ja) 2011-03-31
WO2009091764A3 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
BRPI0813235A2 (pt) Combinação anti-helmíntica.
BRPI0821573A2 (pt) benzofuropirimidonas
ATE501136T1 (de) Imidazopyridinone
DE502007001207D1 (de) Elektrosaugkopf
ATE514696T1 (de) Diphenyl-dihydro-imidazopyridinone
DE112008003636A5 (de) Mehrzuggruppierer
BRPI0811451A2 (pt) Exopolissacarídeo
BRPI0814519A2 (pt) Organopolissiloxano
BRPI0815547A2 (pt) Depsipeptídeos cícliocos
BRPI0812840A2 (pt) 2-imidazolinas
EP2337157A4 (en) CONNECTOR
AT505058A3 (de) Türschliesssystem
BRPI0812994A2 (pt) Microbiocidas
DE112008001216A5 (de) Magnetronplasmaanlage
DE502008001694D1 (de) Mitfahrhubwagen
DE112008003094A5 (de) Geomatte
DE112008003196A5 (de) Handpipettiergerät
EP2158641A4 (en) Connector
DE502008003063D1 (de) Magnetventilinjektor
BRPI0906846A2 (pt) Beta-lactamas terapêuticas.
DE112008002200A5 (de) Sperrsynchronisiervorrichtung
CU20090155A7 (es) Macrolidos
IT1396642B1 (it) Statore.
ATE519980T1 (de) Verbinder
DE502008000815D1 (de) Kraftfahrzeugsitzverstellantrieb

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.